|Description||ON123300, a dihydropyrido[2,3-d]pyrimidine derivative, has been found to be an effective multikinase inhibitor that could be probably used against brain tumor and mantle cell lymphomas. It is still under preclinical trials in Colorectal cancer. IC50: 3.8|
|Synonyms||UNII-QJ8RO3296G; QJ8RO3296G; CHEMBL3115681; ON123300; SCHEMBL10050883; BDBM50447512|
|Solubility||10 mM in DMSO|
|Application||ON123300 has been found to be an effective multikinase inhibitor that could be probably used against brain tumor and mantle cell lymphomas.|
|Shelf Life||As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly|
|Current Developer||Icahn School of Medicine at Mount Sinai; Onconova Therapeutics|
Ca2+ Channel Agonist 1
A Ca2+ Channel Agonist that selectively acting on N-type Ca2+ channel and also be found to restrain the cdk activity at some extent. IC50: 14.23 uM (EC50, Ca2+ ...
Senexin A is a selective Cell division protein kinase 8 (CDK8) inhibitor with IC50 value of 280 nM. Senexin A can bind to cdk19 in an ATP-competitive manner and...
Kenpaullone is a potent inhibitor of CDK1/cyclin B (IC50 = 400 nM), CDK2/cyclin A (IC50 = 680 nM), CDK2/cyclin E (IC50 = 7.5 uM) and CDK5/p25 (IC50 = 850 nM). K...
AU-12122 is a novel-developed CDK7 inhibitor, which is potent and orally bioactive. It induces apoptosis of acute monocytic leukemia THP-1.
PHA-793887 is an inhibitor of multiple cyclin dependent kinases (CDK) with activity against CDK2, CDK1 and CDK4. Although toxicity was acceptable at initial dos...
ICEC-0942 is a small-molecule cyclin-dependent kinase 7 (CDK7) inhibitor developed for cancer therapy. Pre-clinical study in Acute Myeloid Leukaemia (AML) model...
BIO (6-bromoindirubin-3'-oxime) is a specific inhibitor of GSK-3 with IC50 of 5 nM for GSK-3α/β, shows >16-fold selectivity over CDK5, also a pan-JAK inhibitor.
Aloisine a is a cell-permeable pyrrolo-pyrazine compound that acts as a potent, selective, reversible, and ATP-competitive inhibitor of cyclin dependent kinases...
NG 52 is a tri-substituted purine that binds to the ATP-binding site of yeast cyclin-dependent kinases, inhibiting Cdc28p and Pho85p (IC50s = 7 and 2 µM, respec...
CGP-79807 is a potent CDC2 protein kinase inhibitor that originated by Novartis. In Sep 2000, Preclinical development for Cancer in Switzerland was on-going, bu...
Alvocidib is a synthetic N-methylpiperidinyl chlorophenyl flavone compound. As an inhibitor of cyclin-dependent kinase, alvocidib induces cell cycle arrest by p...
WHI-P180 moderately inhibited ABCG2 function, exhibiting weak phototoxicity. The elimination half-life of WHI-P180 in CD-1 mice (BALB/ c mice) following i.v., i...
QS-1189 is a reversible, high selective, orally available cyclin-dependent kinase 7 (CDK7) inhibitor developed for cancer therapy. QS-1189 exhibits antitumor ac...
PHA-767491 is a potent, ATP-competitive dual cdc7/cdk9 inhibitor (IC50 values are 10 and 34 nM respectively) that prevents initiation of DNA replication.
PHA-767491 hydrochloride is a potent, ATP-competitive dual Cdc7/Cdk9 inhibitor, which prevents initiation of DNA replication. It inhibits cell proliferation in ...
AT 7519 mesylate
AT 7519 mesylate is a small-molecule inhibitor of CDK including CDK 1, 2 , 4, 5, 6, and 9 in vitro and it induces apoptosis in multiple myeloma via GSK-3β activ...
LEE011 is an orally bioavailable and highly specific CDK4/6 (cyclin-dependent kinase 4/6) inhibitor. LEE011 in combination with LGX818 (a V600E BRAF specific in...
Milciclib is an orally bioavailable inhibitor of cyclin-dependent kinases (CDKs) and thropomyosin receptor kinase A (TRKA), with potential antineoplastic activi...
BS-181 is a highly selective CDK inhibitor for CDK7 with an IC(50) of 21 nmol/L. Testing of other CDKs as well as another 69 kinases showed that BS-181 only inh...
Riviciclib, also known as P276-00, is a novel CDK1, CDK4 and CDK9 inhibitor with IC50 of 79 nM, 63 nM and 20 nM, respectively. P276-00 selectively binds to and ...